203153 - A post-marketing, observational, retrospective, cohort study to assess the safety of RefortrixTM (Tdap) when administered during pregnancy in a maternal immunization program in Brazil

First published 20/05/2016

Last updated 02/07/2024

EU PAS number:

EUPAS13406

Study

Finalised

Documents

Study protocol

Initial protocol

gsk-203153-protocol-redact

English (734.52 KB - PDF) View document

Study results

gsk-203153-clinical-study-report-redact

English (5.48 MB - PDF) View document

Study report

Other information

Publications

Study publications

Secondary tabs